Gisela M. Schwab, M.D., has served as Executive Vice President and Chief Medical Officer since January 2008 of Exelixis, Inc. She joined Exelixis in 2006 as Senior Vice President and Chief Medical Officer. From 2002 to 2006, she held the position of Senior Vice President and Chief Medical Officer at Abgenix, Inc., a human antibody-based drug development company. She also served as Vice President, Clinical Development at Abgenix from 1999 to 2001. Prior to working at Abgenix, from 1992 to 1999, she held positions of increasing responsibility at Amgen Inc., most recently as Director of Clinical Research and Haematology/Oncology Therapeutic Area Team Leader. From August 2011 to July 2014, Dr. Schwab has served as a member of the Board of Directors of Topotarget A/S, a publicly-held biopharmaceutical company. Current board position: Cellerant Therapeutics, Inc.
She received her Doctor of Medicine degree from the University of Heidelberg, trained at the University of Erlangen-Nuremberg and the National Cancer Institute, Bethesda Maryland, USA, and is board certified in internal medicine and haematology and oncology. She is a German citizen, and resides in the U.S.